Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
- Type
- Retraction
- Notice date
- 1/25/2024 0:00
- Journal
- PLoS One
- Publisher
- PLoS
- Notice DOI
- 10.1371/journal.pone.0298013
- Original paper DOI
- 10.1371/journal.pone.0028841